

John E Harrison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2502602/publications.pdf>

Version: 2024-02-01

77
papers

3,533
citations

185998

28
h-index

143772

57
g-index

100
all docs

100
docs citations

100
times ranked

5161
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, efficacy, and biomarker findings of PBT2 in targeting A β as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2008, 7, 779-786.	4.9	657
2	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 509-516.	1.2	347
3	Efficacy of Souvenaid in Mild Alzheimer's Disease: Results from a Randomized, Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 225-236.	1.2	256
4	A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials. <i>Archives of Neurology</i> , 2007, 64, 1323.	4.9	189
5	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 21.	3.0	183
6	Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. <i>Alzheimer's and Dementia</i> , 2017, 13, 468-492.	0.4	131
7	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). <i>Trials</i> , 2019, 20, 191.	0.7	127
8	The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 873-881.	1.1	100
9	Cognitive Impairment Associated with Cancer: A Brief Review. <i>Innovations in Clinical Neuroscience</i> , 2018, 15, 36-44.	0.1	99
10	Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project. <i>Alzheimer's and Dementia</i> , 2017, 13, 186-195.	0.4	85
11	Safety, tolerability and efficacy of the glutaminy cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 107.	3.0	80
12	Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 8.	3.0	69
13	Evaluation of Speech-Based Digital Biomarkers: Review and Recommendations. <i>Digital Biomarkers</i> , 2020, 4, 99-108.	2.2	66
14	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 521-534.	5.3	64
15	FDA position statement "Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry". <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 13-19.	1.8	59
16	Minimal Cognitive Impairment in UK HIV-Positive Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 120-127.	0.9	58
17	No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. <i>European Heart Journal</i> , 2018, 39, 374-381.	1.0	57
18	Cognitive function after clinical remission in patients with melancholic and non-melancholic depression: A 6 month follow-up study. <i>Journal of Affective Disorders</i> , 2015, 171, 85-92.	2.0	55

#	ARTICLE	IF	CITATIONS
19	A randomized placebo controlled trial of vitamin B12 supplementation to prevent cognitive decline in older diabetic people with borderline low serum vitamin B12. <i>Clinical Nutrition</i> , 2017, 36, 1509-1515.	2.3	48
20	A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients. <i>Clinical Nutrition</i> , 2020, 39, 2399-2405.	2.3	48
21	The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. <i>Journal of Psychopharmacology</i> , 2022, 36, 114-125.	2.0	47
22	Which Cognitive Domains are Improved by Treatment with Vortioxetine?. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw054.	1.0	46
23	Exploring the contribution of spatial navigation to cognitive functioning in older adults. <i>Neurobiology of Aging</i> , 2017, 51, 67-70.	1.5	45
24	Tolerability and Safety of Souvenaid in Patients with Mild Alzheimer's Disease: Results of Multi-Center, 24-Week, Open-Label Extension Study. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 471-480.	1.2	44
25	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 222, 14-20.	2.0	39
26	A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 106.	3.0	37
27	Cognitive impairment in remitted and non-remitted depressive patients: A follow-up comparison between first and recurrent episodes. <i>European Neuropsychopharmacology</i> , 2015, 25, 1991-1998.	0.3	35
28	Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1131-1139.	1.2	34
29	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 47.	3.0	32
30	Stability, reliability, and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, e1736.	1.1	27
31	A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 130-138.	1.8	26
32	Scopolamine disrupts place navigation in rats and humans: a translational validation of the Hidden Goal Task in the Morris water maze and a real maze for humans. <i>Psychopharmacology</i> , 2017, 234, 535-547.	1.5	24
33	Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 45.	3.0	19
34	Measuring the mind: assessing cognitive change in clinical drug trials. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 471-473.	1.3	18
35	Analysing UK clinicians' understanding of cognitive symptoms in major depression: A survey of primary care physicians and psychiatrists. <i>Journal of Affective Disorders</i> , 2017, 207, 346-352.	2.0	18
36	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. <i>CNS Spectrums</i> , 2019, 24, 154-162.	0.7	18

#	ARTICLE	IF	CITATIONS
37	The Cognitiveâ€Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catchâ€Cog study cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12020.	1.8	18
38	The evaluation of cognitive function in the dementias: methodological and regulatory considerations. <i>Dialogues in Clinical Neuroscience</i> , 2003, 5, 77-88.	1.8	18
39	Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease. <i>American Journal of Neurodegenerative Disease</i> , 2014, 3, 158-69.	0.1	14
40	Cognition in MCI and Alzheimerâ€™s Disease: Baseline Data from a Longitudinal Study of the NTB. <i>Clinical Neuropsychologist</i> , 2014, 28, 252-268.	1.5	13
41	Selection of cognitive tests for trials of therapeutic agents. <i>Lancet Psychiatry</i> , 2016, 3, 499.	3.7	13
42	A novel cognitiveâ€functional composite measure to detect changes in early Alzheimer's disease: Testâ€retest reliability and feasibility. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 153-160.	1.2	12
43	Cognitive Approaches to Early Alzheimer's Disease Diagnosis. <i>Medical Clinics of North America</i> , 2013, 97, 425-438.	1.1	11
44	Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it). <i>Scandinavian Journal of Pain</i> , 2017, 15, 62-67.	0.5	11
45	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2018, 238, 228-232.	2.0	11
46	Charles Darwin's Emotional Expression â€Experimentâ€and His Contribution to Modern Neuropharmacology. <i>Journal of the History of the Neurosciences</i> , 2010, 19, 158-170.	0.1	9
47	PSYCHOMETRIC EVALUATION OF THE NEUROPSYCHOLOGICAL TEST BATTERY IN INDIVIDUALS WITH NORMAL COGNITION, MILD COGNITIVE IMPAIRMENT, OR MILD TO MODERATE ALZHEIMERâ€™S DISEASE: RESULTS FROM A.5 LONGITUDINAL STUDY. <i>Journal of Prevention of Alzheimer's Disease</i> , 2018, 5, 1-9.	1.5	8
48	Cognition comes of age: comments on the new FDA draft guidance for early Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 61.	3.0	8
49	Screening and measurement of cognitive impairment in psychiatry. <i>CNS Spectrums</i> , 2019, 24, 144-153.	0.7	7
50	Cognitive Functions as Predictors of Alzheimerâ€™s Disease Biomarker Status in the European Prevention of Alzheimerâ€™s Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1203-1210.	1.2	7
51	Remote data collection speech analysis and prediction of the identification of Alzheimerâ€™s disease biomarkers in people at risk for Alzheimerâ€™s disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol. <i>BMJ Open</i> , 2022, 12, e052250.	0.8	7
52	Evaluation of the effect of Cooled HaEmodialysis on Cognitive function in patients suffering with end-stage KidnEy Disease (E-CHECKED): feasibility randomised control trial protocol. <i>Trials</i> , 2020, 21, 820.	0.7	6
53	Asynchronous Remote Assessment for Cognitive Impairment: Reliability Verification of the Neurotrack Cognitive Battery. <i>JMIR Formative Research</i> , 2022, 6, e34237.	0.7	6
54	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimerâ€™s Disease: Towards a More Continuous Approach. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 511-524.	1.2	5

#	ARTICLE	IF	CITATIONS
55	The Assessment of Cognition in Translational Medicine: A Contrast Between the Approaches Used in Alzheimer's Disease and Major Depressive Disorder. Handbook of Behavioral Neuroscience, 2019, 29, 297-308.	0.7	4
56	Assessment of Cognitive Outcome Measures in Teenagers with 15q13.3 Microdeletion Syndrome. Journal of Autism and Developmental Disorders, 2016, 46, 1455-1463.	1.7	3
57	Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development. Drug Discovery Today, 2021, 26, 1330-1336.	3.2	3
58	Further validation of the THINC-it tool and extension of the normative data set in a study of 1019 typical controls. International Journal of Methods in Psychiatric Research, 2022, 31, .	1.1	3
59	Routine cognitive testing for all drugs?. Drug Discovery Today, 2002, 7, 101-102.	3.2	2
60	Commentary: Composite cognitive and functional measures for early stage Alzheimer's disease trials. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12009.	1.2	2
61	[P3-015]: THE IMPACT OF ELECTRONIC CLINICAL OUTCOME ASSESSMENTS (ECO) ON ALZHEIMER'S DISEASE CLINICAL TRIAL DATA QUALITY. Alzheimer's and Dementia, 2017, 13, P935.	0.4	1
62	[P4-578]: EXPANDING THE BRIEF ASSESSMENT OF COGNITION (BACAPP) FOR ASSESSMENT OF COGNITION IN AGING: INITIAL FINDINGS FROM AN ONGOING NORMATIVE STUDY. Alzheimer's and Dementia, 2017, 13, P1574.	0.4	1
63	P4-123: Scopolamine disrupts allocentric spatial navigation in humans: The study in a real-space analogue of the morris water maze. , 2015, 11, P825-P825.		0
64	P2-300: Capturing Changes in Cognition: The Needs and Wishes of Dementia Researchers and Clinicians. , 2016, 12, P748-P748.		0
65	[P4-008]: QUALITY ASPECTS OF A NOVEL COGNITIVE-FUNCTIONAL COMPOSITE FOR THE MEASUREMENT OF DISEASE PROGRESSION IN ALZHEIMER'S DISEASE: FEASIBILITY, TEST-RETEST RELIABILITY AND PRACTICE EFFECTS. Alzheimer's and Dementia, 2017, 13, P1256.	0.4	0
66	P4-113: COMPARING THE COGNITIVE-FUNCTIONAL COMPOSITE WITH TRADITIONAL TESTS OF COGNITION AND FUNCTION: FINDINGS FROM THE CATCH-COG STUDY COHORT. Alzheimer's and Dementia, 2018, 14, P1482.	0.4	0
67	P3-225: PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NON-DIABETIC ALZHEIMER'S PATIENTS. Alzheimer's and Dementia, 2018, 14, P1157.	0.4	0
68	Behavioural symptoms in Alzheimer's disease are associated with white matter lesions (WML) volume and are independent of atrophy and hypometabolism. Alzheimer's and Dementia, 2020, 16, e045223.	0.4	0
69	Influence of cerebral glucose metabolic rate on cognitive function in Alzheimer's subjects. Alzheimer's and Dementia, 2020, 16, e045899.	0.4	0
70	Assessing the relationship between cognitive dysfunction and brain atrophy in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046004.	0.4	0
71	Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral glucose metabolic rate in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046068.	0.4	0
72	Keith Andrew Wesnes in memoriam. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12085.	1.2	0

#	ARTICLE	IF	CITATIONS
73	The Assessment of Cognitive Dysfunction in Major Depressive Disorder. , 2019, , 59-72.		0
74	The Use and Development of Clinical Measures of Alzheimerâ€™s Disease Trials. , 2022, , 281-291.		0
75	Capturing functional change in early Alzheimerâ€™s disease: Comparing instruments and scoring techniques to detect subtle decline. Alzheimer's and Dementia, 2021, 17, .	0.4	0
76	Empirical evidence of cognitive change: Calculating reliable change indices for digital tests of cognition in individuals living with Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
77	Utilization of a novel digital neuropsychological assessment Suite in patients with Alzheimerâ€™s disease and cognitive healthy controls: A preliminary investigation. Alzheimer's and Dementia, 2021, 17, .	0.4	0